Bilateral orchidectomy in three metastatic prostate cancer patients with failed LHRH-agonist therapy [8]

South African Medical Journal

Volumn 96, Issue 9, 2006, Pages 810-811

  Olapade Olaopa, E O ^a   Oluwasola, A O ^a   Shonibare, A ^b   Falebita, O A ^a   Akang, E E ^a   Shokunbi, M T ^a  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b St Nicholas Hospital   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANTIGEN DETECTION; CANCER HORMONE THERAPY; CANCER STAGING; CASE REPORT; EMERGENCY SURGERY; GLEASON SCORE; HISTOPATHOLOGY; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; LETTER; MALE; METASTASIS; ORCHIECTOMY; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SPINAL CORD COMPRESSION; TESTIS ATROPHY; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ATROPHY; DISEASE PROGRESSION; GOSERELIN; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTIS; TESTOSTERONE; TREATMENT FAILURE;

EID: 33749074497     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Huggins C jun, Hodges C. Studies on prostatic cancer; effects of castration on advanced carcinoma of prostate gland. Arch Surg 1941; 43: 209.
2. Kozlowski J. Carcinoma of the prostate. In: Gillenwater J, Grayhack J, Howards S, Mitchell M, eds. Adult and Pediatric Urology. Philadelphia: Lippincott Williams & Wilkins, 2002: 1471-1653.
3. Eisenberger M, Blumenstein B, Crawford F, et al. Bilateral orchidectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042.
4. Damyanov C, Tzingliev B, Tabakov V. Treatment of an orchidectomised patient with hormone-refractory prostate cancer with LH-RH agonists. Eur Urol 2001; 40: 474-477.
5. Ornstein D, Smith D, Andriole G. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology 1998; 52: 1094-1097.
6. Tan A, Tuckey J, Rice M. Orchidectomy following failure of antiandrogen therapy in patients with metastatic prostate cancer. Eur Urol 2001; 40: 130-134.
7. Curry E, Sweeney C. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer. J Urol 2002; 168: 193.
8. Krongrad A, Brady J, Rodriguez R. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer. South Med J 1997; 90: 460-461.
9. Oefelein M, Conum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 726-729.
10. Kinouchi T, Maeda O, Ono Y, Meguro N, Kuroda M, Usami M. Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. Int J Urol 2002; 9: 359-361.